The bone marrow has been widely recognised to host a unique microenvironment that facilitates tumour colonisation. Bone metastasis frequently occurs in the late stages of malignant diseases such as breast, prostate and lung cancers. The biology of bone metastasis is determined by tumour-cell-intrinsic traits as well as their interaction with the microenvironment. The bone marrow is a dynamic organ in which various stages of haematopoiesis, osteogenesis, osteolysis and different kinds of immune response are precisely regulated. These different cellular components constitute specialised tissue microenvironments-niches-that play critical roles in controlling tumour cell colonisation, including initial seeding, dormancy and outgrowth. In this review, we will dissect the dynamic nature of the interactions between tumour cells and bone niches. By targeting certain steps of tumour progression and crosstalk with the bone niches, the development of potential therapeutic approaches for the clinical treatment of bone metastasis might be feasible.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184962 | PMC |
| http://dx.doi.org/10.1038/s41416-021-01329-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgery of the Primary Tumor in de novo Metastatic Breast Cancer: A Palliative Approach or a Potential Survival Game-Changer?
Ann Ital Chir
March 2025
Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Approximately 5-10% of primary breast cancer cases present as de novo stage IV disease, characterized by distant metastases at diagnosis. Traditionally, systemic therapies such as chemotherapy, endocrine therapy and targeted treatments have formed the cornerstone of treatment for metastatic breast cancer (MBC), focusing on disease control, symptom palliation and quality of life improvement. While systemic therapies remain crucial, the role of local treatments, particularly surgery for the primary tumor, is increasingly debated.
View Article and Find Full Text PDFHybrid membranes-mediated biomimetic-nanoparticle carrying miR-665 for effective tumor treatment by remodeling tumor microenvironment.
Int J Pharm
March 2025
Department of Orthopaedics, Affiliated Hospital of Nantong University, Nantong City, Jiangsu Province, PR China. Electronic address:
Background: Osteosarcomas (OS) are malignant bone tumors prevalent in adolescents, characterized by aggressiveness and early metastasis. Current treatments including surgery and chemotherapy face challenges due to drug limitations and the complex tumor microenvironment (TME).
Methods: Tumour membranes (TM) derived from OS cells and macrophage membranes (MM) derived from macrophages were mixed to create hybrid membranes (HM), which were subsequently used to encapsulate microRNA-665(miR-665)-loaded Poly lactic-co-glycolic acid (PLGA) nanoparticles, forming HM@PLGA/miR-665 complexes.
Palliative management of painful pelvic bone metastasis using percutaneous thermal ablation and cement-augmented osteoplasty: A case report.
Int J Surg Case Rep
March 2025
Orthopaedics and Traumatology Department, Hasan Sadikin Hospital, Padjajaran University, Bandung, Indonesia.
Introduction And Importance: Bone metastases are common in advanced malignancies, particularly from breast and prostate cancers, leading to significant morbidity due to pain, functional impairment, and skeletal-related events. This case report discusses a multidisciplinary approach using minimally invasive techniques for managing a challenging supracetabular metastatic lesion.
Case Presentation: A 46-year-old female with metastatic bone disease in the right supracetabular pelvic region secondary to primary breast cancer presented with severe pain (Numeric Analog Scale [NAS] 7-8) and functional impairment.
Integrated analysis of multiple programmed cell death-related prognostic genes and functional validation of apoptosis-related genes in osteosarcoma.
Int J Biol Macromol
March 2025
Department of Orthopedic Surgery, Orthopedic Oncology Institute, The Second Affiliated Hospital of Air Force Medical University, Xi'an, China. Electronic address:
Osteosarcoma (OS) is one of the most prevalent bone malignancies with a poor prognosis. Various types of programmed cell death patterns can influence cancer progression and response to treatment. We aimed to integrate different molecular characteristics of cell death for risk stratification and personalized therapy.
View Article and Find Full Text PDFLocal therapy for oligometastatic prostate cancer.
Jpn J Clin Oncol
March 2025
Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Traditionally, systemic therapy based on androgen deprivation therapy (ADT) has been the primary approach for treating metastatic prostate cancer. Local therapies targeting metastatic lesions have rarely been employed for cancer control. However, the advent of next-generation imaging modalities, such as choline positron emission tomography (PET), whole-body magnetic resonance imaging, and prostate-specific membrane antigen (PSMA)-PET, has enabled the detection of oligometastases that were previously undetectable using conventional imaging techniques, such as computed tomography and bone scintigraphy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!